Yohannes Tesfaigzi to Lung Neoplasms
This is a "connection" page, showing publications Yohannes Tesfaigzi has written about Lung Neoplasms.
Connection Strength
1.444
-
Tessema M, Tassew DD, Yingling CM, Do K, Picchi MA, Wu G, Petersen H, Randell S, Lin Y, Belinsky SA, Tesfaigzi Y. Identification of novel epigenetic abnormalities as sputum biomarkers for lung cancer risk among smokers and COPD patients. Lung Cancer. 2020 08; 146:189-196.
Score: 0.560
-
Bruse S, Petersen H, Weissfeld J, Picchi M, Willink R, Do K, Siegfried J, Belinsky SA, Tesfaigzi Y. Increased methylation of lung cancer-associated genes in sputum DNA of former smokers with chronic mucous hypersecretion. Respir Res. 2014 Jan 09; 15:2.
Score: 0.360
-
Tesfaigzi Y, Wright PS, Belinsky SA. SPRR1B overexpression enhances entry of cells into the G0 phase of the cell cycle. Am J Physiol Lung Cell Mol Physiol. 2003 Oct; 285(4):L889-98.
Score: 0.173
-
Tessema M, Yingling CM, Picchi MA, Wu G, Liu Y, Weissfeld JL, Siegfried JM, Tesfaigzi Y, Belinsky SA. Epigenetic Repression of CCDC37 and MAP1B Links Chronic Obstructive Pulmonary Disease to Lung Cancer. J Thorac Oncol. 2015 Aug; 10(8):1181-8.
Score: 0.100
-
Leng S, Liu Y, Weissfeld JL, Thomas CL, Han Y, Picchi MA, Edlund CK, Willink RP, Gaither Davis AL, Do KC, Nukui T, Zhang X, Burki EA, Van Den Berg D, Romkes M, Gauderman WJ, Crowell RE, Tesfaigzi Y, Stidley CA, Amos CI, Siegfried JM, Gilliland FD, Belinsky SA. 15q12 variants, sputum gene promoter hypermethylation, and lung cancer risk: a GWAS in smokers. J Natl Cancer Inst. 2015 Feb 23; 107(5).
Score: 0.097
-
Belinsky SA, Grimes MJ, Picchi MA, Mitchell HD, Stidley CA, Tesfaigzi Y, Channell MM, Liu Y, Casero RA, Baylin SB, Reed MD, Tellez CS, March TH. Combination therapy with vidaza and entinostat suppresses tumor growth and reprograms the epigenome in an orthotopic lung cancer model. Cancer Res. 2011 Jan 15; 71(2):454-62.
Score: 0.073
-
Wang X, Chen W, Zeng W, Bai L, Tesfaigzi Y, Belinsky SA, Lin Y. Akt-mediated eminent expression of c-FLIP and Mcl-1 confers acquired resistance to TRAIL-induced cytotoxicity to lung cancer cells. Mol Cancer Ther. 2008 May; 7(5):1156-63.
Score: 0.061
-
Leng S, Stidley CA, Liu Y, Edlund CK, Willink RP, Han Y, Landi MT, Thun M, Picchi MA, Bruse SE, Crowell RE, Van Den Berg D, Caporaso NE, Amos CI, Siegfried JM, Tesfaigzi Y, Gilliland FD, Belinsky SA. Genetic determinants for promoter hypermethylation in the lungs of smokers: a candidate gene-based study. Cancer Res. 2012 Feb 01; 72(3):707-15.
Score: 0.019